CARM has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
CARM has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
CARISMA Therapeutics's revenue per share for the three months ended in Jun. 2024 was $0.22. CARISMA Therapeutics's revenue per share for the trailing twelve months (TTM) ended in Jun. 2024 was $0.51.
During the past 12 months, the average Revenue Per Share Growth Rate of CARISMA Therapeutics was 1.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate.
The historical rank and industry rank for CARISMA Therapeutics's Revenue per Share or its related term are showing as below:
The historical data trend for CARISMA Therapeutics's Revenue per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CARISMA Therapeutics Annual Data | |||||||||
Trend | Dec20 | Dec21 | Dec22 | Dec23 | |||||
Revenue per Share | - | - | 0.24 | 0.45 |
CARISMA Therapeutics Quarterly Data | |||||||||||||
Dec20 | Jun21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | |
Revenue per Share | Get a 7-Day Free Trial | 0.09 | 0.10 | 0.11 | 0.08 | 0.22 |
For the Biotechnology subindustry, CARISMA Therapeutics's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, CARISMA Therapeutics's PS Ratio distribution charts can be found below:
* The bar in red indicates where CARISMA Therapeutics's PS Ratio falls into.
Revenue per Share is the amount of Revenue per outstanding share of the company's stock.
Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.
CARISMA Therapeutics's Revenue Per Share for the fiscal year that ended in Dec. 2023 is calculated as
Revenue Per Share (A: Dec. 2023 ) | = | Revenue (A: Dec. 2023 ) | / | Shares Outstanding (Diluted Average) (A: Dec. 2023 ) |
= | 14.919 | / | 33.524 | |
= | 0.45 |
CARISMA Therapeutics's Revenue Per Share for the quarter that ended in Jun. 2024 is calculated as
Revenue Per Share (Q: Jun. 2024 ) | = | Revenue (Q: Jun. 2024 ) | / | Shares Outstanding (Diluted Average) (Q: Jun. 2024 ) |
= | 9.197 | / | 41.544 | |
= | 0.22 |
Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.51
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CARISMA Therapeutics (NAS:CARM) Revenue per Share Explanation
In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.
Peter Lynch categorized companies according to their revenue growth:
Slow Grower: Inflation < 10-Year Revenue Growth Rate < 10%:His favorite companies are stalwart, those growing between 10-20% a year.
Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.
Be Aware
Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.
Thank you for viewing the detailed overview of CARISMA Therapeutics's Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.
Modernatx, Inc. | 10 percent owner | 200 TECHNOLOGY SQUARE, CAMBRIDGE MA 02139 |
Sanford S Zweifach | director | 21720 23RD DRIVE SE, SUITE 150, BOTHELL WA 98021 |
Steven Kelly | director, officer: President and CEO | C/O INNOVIVE PHARMACEUTICALS, INC., 555 MADISON AVENUE, 25TH FLOOR, NEW YORK NY 10022 |
Briggs Morrison | director | C/O SYNDAX PHARMACEUTICALS, INC., 400 TOTTEN POND ROAD, SUITE 110, WALTHAM MA 02451 |
Richard Steven Morris | officer: Chief Financial Officer | 397 EAGLEVIEW BOULEVARD, EXTON PA 19341 |
Chidozie Ugwumba | director | 158 FILMORE STREET, DENVER CO 80206 |
Michael Klichinsky | officer: Chief Scientific Officer | C/O CARISMA THERAPEUTICS INC., 3675 MARKET STREET, SUITE 200, PHILADELPHIA PA 19104 |
Michael Torok | director | C/O CARISMA THERAPEUTICS INC., 3675 MARKET STREET, SUITE 200, PHILADELPHIA PA 19104 |
Regina Hodits | director | C/O CARISMA THERAPEUTICS INC., 3675 MARKET STREET, SUITE 200, PHILADELPHIA PA 19104 |
Bjorn Odlander | director | C/O ODLANDER, FREDRIKSON & CO. AB, STRANDVAGEN 5B, STOCKHOLM V7 SE-114 51 |
Minori Rosales | officer: Chief Development Officer | 245 FIRST STREET, SUITE 1800, CAMBRIDGE MA 02142 |
Jewett Michael A. S. | director | C/O SESEN BIO, INC., 245 FIRST STREET, SUITE 1800, CAMBRIDGE MA 02142 |
Peter Honig | director | 3344 N. TORREY PINES COURT, SUITE 200, LA JOLLA CA 92037 |
Patricia M. Drake | officer: Chief Commercial Officer | 245 FIRST STREET, SUITE 1800, CAMBRIDGE MA 02142 |
Elly Ryu | officer: Principal Accounting Officer | 245 FIRST STREET, SUITE 1800, CAMBRIDGE MA 02142 |
From GuruFocus
By PRNewswire • 05-30-2024
By PRNewswire • 08-06-2024
By PRNewswire • 06-25-2024
By GuruFocus Research • 02-06-2024
By PRNewswire • 05-08-2024
By GuruFocus Research • 02-06-2024
By PRNewswire • 05-06-2024
By GuruFocus Research • 02-06-2024
By PRNewswire • 04-24-2024
By PRNewswire • 08-06-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.